Microvesicles Correlated with Components of Metabolic Syndrome in Men with Type 2 Diabetes Mellitus and Lowered Testosterone Levels But Were Unaltered by Testosterone Therapy
Table 1
Baseline characteristics of study population.
Placebo ()
Testosterone ()
Age
59,5 (6,3)
61,4 (6)
0,3367
Smoking status (current/previous/never)
4/9/6
3/12/4
BMI (kg m−2)
30,8 (3,8)
30,6 (4)
0,8879
Waist circumference (cm)
105,8 (10,8)
106,9 (10)
0,7577
Total fat mass (kg)
27,9 (6,5)
26,9 (22,6; 34,8)
0,7837
Lean body mass (kg)
61,7 (7,5)
61,9 (8,9)
0,9531
Systolic blood pressure (mmHg)
138,2 (12,8)
137,7 (16,7)
0,9151
Diastolic blood pressure (mmHg)
81,7 (8,2)
80,5 (11,1)
0,6948
HbA1c (% Hb)
6,50 (6,15; 6,80)
6,52 (0,53)
0,8108
Total cholesterol (mmol L−1)
3,8 (1,1)
4,0 (0,7)
0,5511
LDL (mmol L−1)
2,2 (0,8)
2,3 (0,7)
0,6904
HDL (mmol L−1)
0,9 (0,9; 1)
1,0 (0,2)
0,2057
TG (mmol L−1)
1,3 (1,16; 1,58)
1,1 (0,85; 2,05)
0,323
ALT (IU L−1)
31,0 (24,5; 43)
35,7 (17,5)
0,844
GGT (IU L−1)
39,0 (30; 51,5)
31,0 (23,75; 39,25)
0,1123
Fasting glucose (mmol L−1)
6,92 (1,01)
7,14 (1,27)
0,5602
Disposal rate: base
90,0 (12,8)
88,6 (85,39; 109,02)
0,3506
Disposal rate: clamp
179,4 (42,1)
155,9 (136,34; 198,84)
0,5877
ΔRd
89,4 (40,6)
89,8 (14,9)
0,9655
HGP: base
83,2 (13,2)
89,8 (14,9)
0,1516
HGP: clamp
32,2 (24,57; 38,64)
28,9 (22,02; 40,88)
0,7284
C-peptide: base
1127,8 (318,7)
933,5 (859,25; 1306)
0,422
Insulin: fasting
103,8 (55,9)
89,5 (47,8)
0,4028
Insulin clearance
0,4 (0,1)
0,3 (0,28; 0,33)
0,1912
Data are depicted as mean (SD) or median (Q25%; Q75%). Smoking status for 1 person in the testosterone group is unknown. Difference in disposal rate at baseline and during clamp.
